Quadra Logic Technologies Inc. on Tuesday said it has filedadditional data with the Canadian Health Protection Board,which is considering the company's application for marketingapproval for Photofrin porfimer sodium, a treatment for lung,bladder and esophageal cancer.
The Vancouver, British Columbia, company (NASDAQ:QLTIF)submitted the original application in July 1989 based on PhaseII trials. The HPB requested additional clinical data lastDecember, and QLT provided additional safety and efficacydata from Phase II and III trials on 375 patients.
QLT's partner in Canada, American Cyanamid Co.'s Canadianaffiliate, is conducting the regulatory process for the product.QLT also filed for approval in Denmark and Belgium in Marchand is seeking regulatory approval throughout Europe. -- BD
(c) 1997 American Health Consultants. All rights reserved.